Original press release link here.
GPC to Host Forum on Payer Policies for Liquid Biopsy & Emerging Clinical Genomics
August 1, 2016
The Green Park Collaborative (GPC) will host a Genomics Technology Policy Forum November 2 and 3 in Baltimore, Maryland.
The two-day forum will foster in-depth discussions on evidence, utility, and value between innovators, payers, and other key stakeholders shaping the future of genomics for patient care.
FOR IMMEDIATE RELEASE
Baltimore, Maryland (August 1, 2016) – The Green Park Collaborative (GPC) will host a Genomics Technology Policy Forum November 2 and 3 in Baltimore, Maryland. The two-day forum will foster in-depth discussions on evidence, utility, and value between innovators, payers, and other key stakeholders shaping the future of genomics for patient care.
This event will bring together a number of esteemed speakers and key thought leaders to participate in three sessions focused on health systems and genomic innovations, liquid biopsy, and panomics. These sessions will include panel presentations and interactive plenary discussions aimed at engaging participants in dialogue and debate surrounding these emerging technologies.
“Promoting understanding between innovators and payers on emerging clinical applications of genomic technologies is critical for the advancement of personalized medicine,” said Donna Messner, the Director of GPC, “so we look forward to convening a meeting of numerous experts and stakeholders in this field to advance this important discussion.”
Marc S. Williams of Geisinger Health System, Sunil Budhrani of Innovation Health, and Lincoln Nadauld of Intermountain Healthcare will anchor the Health Systems and Genomic Innovations session, which will focus on how integrated health systems serve as incubators of clinical innovation and evidence development. It will also touch upon how they are incorporating genomics into clinical care, why they are doing it, and what they are learning from it.
A session focusing on emerging applications and coverage for liquid biopsy will feature Joseph Chin of the Centers for Medicare & Medicaid Services, Bruce Quinn of FaegreBD, Robert McDonough of Aetna, Reena Philip of the Food & Drug Administration, and Girish Putcha of Palmetto GBA. This session will highlight case studies (such as FDA’s recent approval of its first liquid biopsy test and a recent study demonstrating some clinical advantages of liquid biopsy) to examine evidentiary standards for liquid biopsies with an emphasis on clinical utility.
Evidence and coverage challenges for expanding genomic testing and "panomics" will be the focus of a third major session. This session will examine payer decision making in specific case examples such as policies developed for NantHealth’s GPS CancerTM and Foundation Medicine's FoundationOne Panel. Confirmed panelists include Gary Palmer of NantHealth, Steve Phurrough of the Centers for Medicare and Medicaid Services, and John Fox of Priority Health, among others.
This event will also feature Spotlight presentations on cross-cutting issues from scientific and clinical experts and patient advocates including Jean Claude Zenklusen from the National Cancer Institute, Matthias Holdhoff from the Johns Hopkins School of Medicine, and others.
Attendance is limited to invited participants and corporate sponsor representatives only. If you are interested in attending, please contact GPC for further details and/or sponsorship information.
About GPC
GPC is a multi-stakeholder forum focused on improving clinical evidence and policies for health plan reimbursement. GPC, a major initiative of the Center for Medical Technology Policy (CMTP), convenes working groups to develop condition and technology-specific study design recommendations that focus on real-world effectiveness and value, meet the evidence expectations of payers, and are informed by the views of patients and clinicians.
GPC is a multi-stakeholder forum focused on improving clinical evidence and policies for health plan reimbursement. GPC, a major initiative of the Center for Medical Technology Policy (CMTP), convenes working groups to develop condition and technology-specific study design recommendations that focus on real-world effectiveness and value, meet the evidence expectations of payers, and are informed by the views of patients and clinicians.
Contact
Julie Simmons
Julie.simmons@cmtpnet.org
410-547-2687 x116
Julie Simmons
Julie.simmons@cmtpnet.org
410-547-2687 x116
